Next Article in Journal
Therapeutic Potential of Polyphenols-Loaded Polymeric Nanoparticles in Cardiovascular System
Next Article in Special Issue
Recent Trends in Enzyme Inhibition and Activation in Drug Design
Previous Article in Journal
From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies
Previous Article in Special Issue
Discovery of Novel Tankyrase Inhibitors through Molecular Docking-Based Virtual Screening and Molecular Dynamics Simulation Studies
Review

Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates

1
Dipartimento di Scienze della Salute, Università “Magna Græcia” di Catanzaro, Viale Europa, 88100 Catanzaro, Italy
2
Net4Science srl, Campus Universitario ‘S. Venuta’, Università ‘Magna Græcia’ di Catanzaro, Viale Europa, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Athina Geronikaki
Molecules 2020, 25(15), 3321; https://doi.org/10.3390/molecules25153321
Received: 18 June 2020 / Revised: 18 July 2020 / Accepted: 20 July 2020 / Published: 22 July 2020
The mechanisms of inflammation and cancer are intertwined by complex networks of signaling pathways. Dysregulations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway underlie several pathogenic conditions related to chronic inflammatory states, autoimmune diseases and cancer. Historically, the potential application of JAK inhibition has been thoroughly explored, thus triggering an escalation of favorable results in this field. So far, five JAK inhibitors have been approved by the Food and Drug Administration (FDA) for the treatment of different diseases. Considering the complexity of JAK-depending processes and their involvement in multiple disorders, JAK inhibitors are the perfect candidates for drug repurposing and for the assessment of multitarget strategies. Herein we reviewed the recent progress concerning JAK inhibition, including the innovations provided by the release of JAKs crystal structures and the improvement of synthetic strategies aimed to simplify of the industrial scale-up. View Full-Text
Keywords: Janus kinase (JAK); multitarget; inflammation; cancer; synthetic strategies; tofacitinib; ruxolitinib Janus kinase (JAK); multitarget; inflammation; cancer; synthetic strategies; tofacitinib; ruxolitinib
Show Figures

Figure 1

MDPI and ACS Style

Coricello, A.; Mesiti, F.; Lupia, A.; Maruca, A.; Alcaro, S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 2020, 25, 3321. https://doi.org/10.3390/molecules25153321

AMA Style

Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules. 2020; 25(15):3321. https://doi.org/10.3390/molecules25153321

Chicago/Turabian Style

Coricello, Adriana, Francesco Mesiti, Antonio Lupia, Annalisa Maruca, and Stefano Alcaro. 2020. "Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates" Molecules 25, no. 15: 3321. https://doi.org/10.3390/molecules25153321

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop